Prognostic significance of cytokine modulation in non-small cell lung cancer

被引:45
作者
Neuner, A
Schindel, M
Wildenberg, U
Muley, T
Lahm, H
Fischer, JR
机构
[1] Thoraxklin Heidelberg GGMBH, Immunol Mol Biol Lab, D-69126 Heidelberg, Germany
[2] Thoraxklin Heidelberg GGMBH, Dept Surg, D-69126 Heidelberg, Germany
[3] Thoraxklin Heidelberg GGMBH, Dept Med Oncol, D-69126 Heidelberg, Germany
关键词
non-small cell lung cancer; immunosuppression; interleukin-2; interleukin-10; tumor-derived factors; prognosis;
D O I
10.1002/ijc.10604
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Increased production of immunosuppressive interleukin-10 (IL-10) by non-small cell lung cancer (NSCLC) and increased serum IL-10 concentrations in NSCLC-patients have recently been correlated to reduced survival. We earlier demonstrated suppression of IL-2 secretion in whole blood cell cultures of NSCLC-patients. We now analyzed the influence of IL-2 secretion on survival in NSCLC-patients and the influence of IL-10 on IL-2 secretion. The correlation of the IL-2 producing ability of whole blood cells in response to PHA in 90 NSCLC-patients at the time of diagnosis to survival was calculated by Crit-level, the Kaplan-Meier method and the log-rank test. With a cut-off value of IL-2 production of 1, 100 pg/ml by whole blood cells the difference in survival was significant with a p-value of 0.014. In the group with high and low IL-2, median survival was 14.1 and 9.7 months, respectively. In the subgroup of 33 surgically-treated patients the difference in survival was significant with a p-value of 0.011. In 14 patients with surgical resection of the tumor and high IL-2 at diagnosis and 19 patients with surgical resection, but low IL-2 at diagnosis, median survival was 86.2 and 11.3 months, respectively. Secretion of IL-2 in whole blood cell cultures from healthy individuals was inhibited in a dose-dependent manner upon addition of IL-10. Taken together, suppression of IL-2 secretion has prognostic significance for survival of NSCLC-patients and may be mediated by tumor-derived IL-10. (C) 2002 Wiley-Liss, Inc.
引用
收藏
页码:287 / 292
页数:6
相关论文
共 41 条
[1]  
ABEL U, 1984, METHOD INFORM MED, V23, P154
[2]  
Achiwa H, 1999, CLIN CANCER RES, V5, P1001
[3]  
BENJAMIN D, 1992, BLOOD, V80, P1289
[4]   PRODUCTION OF IL-10 BY MELANOMA-CELLS - EXAMINATION OF ITS ROLE IN IMMUNOSUPPRESSION MEDIATED BY MELANOMA [J].
CHEN, QY ;
DANIEL, V ;
MAHER, DW ;
HERSEY, P .
INTERNATIONAL JOURNAL OF CANCER, 1994, 56 (05) :755-760
[5]  
CHEN WF, 1991, J IMMUNOL, V147, P528
[6]  
COX DR, 1972, J R STAT SOC B, V34, P187
[7]   EXPRESSION OF TRANSFORMING GROWTH-FACTOR-BETA (TGF-BETA) RECEPTORS AND EXPRESSION OF TGF-BETA-1, TGF-BETA-2 AND TGF-BETA-3 IN HUMAN SMALL-CELL LUNG-CANCER CELL-LINES [J].
DAMSTRUP, L ;
RYGAARD, K ;
SPANGTHOMSEN, M ;
POULSEN, HS .
BRITISH JOURNAL OF CANCER, 1993, 67 (05) :1015-1021
[8]   Serum interleukin-10 levels as a prognostic factor in advanced non-small cell lung cancer patients [J].
De Vita, F ;
Orditura, M ;
Galizia, G ;
Romano, C ;
Roscigno, A ;
Lieto, E ;
Catalano, G .
CHEST, 2000, 117 (02) :365-373
[9]  
DE WMR, 1991, J EXP MED, V174, P1209
[10]  
DEL PG, 1993, J IMMUNOL, V150, P353